Kallyope
Founded Year
2015Stage
Grant | AliveTotal Raised
$487.2MLast Raised
$8.2M | 1 yr agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
-123 points in the past 30 days
About Kallyope
Kallyope is a biotechnology company focused on developing oral, small-molecule therapeutics for metabolic, neurological, and gastrointestinal diseases. The company leverages its Klarity™ platform to discover medicines that address conditions such as obesity, diabetes, migraines, and celiac disease through the exploration of the gut-brain axis. Kallyope's innovative approach combines a broad set of integrated technologies to enhance the understanding of gut biology and interorgan signaling pathways. It was founded in 2015 and is based in New York, New York.
Loading...
Loading...
Research containing Kallyope
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Kallyope in 1 CB Insights research brief, most recently on Jan 31, 2022.
Expert Collections containing Kallyope
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Kallyope is included in 2 Expert Collections, including Unicorns- Billion Dollar Startups.
Unicorns- Billion Dollar Startups
1,249 items
Game Changers 2018
36 items
Our selected startups are high-momentum companies pioneering technology with the potential to transform society and economies for the better.
Kallyope Patents
Kallyope has filed 16 patents.
The 3 most popular patent topics include:
- autoimmune diseases
- gastrointestinal tract disorders
- inflammations
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
1/26/2022 | 12/26/2023 | Inflammations, Autoimmune diseases, Gastrointestinal tract disorders, Rare diseases, Syndromes | Grant |
Application Date | 1/26/2022 |
|---|---|
Grant Date | 12/26/2023 |
Title | |
Related Topics | Inflammations, Autoimmune diseases, Gastrointestinal tract disorders, Rare diseases, Syndromes |
Status | Grant |
Latest Kallyope News
Sep 10, 2024
NEW YORK--(BUSINESS WIRE)--Kallyope, a clinical stage biotechnology company discovering and developing novel therapies for diseases with high unmet need, today announced that under the terms of its research collaboration with Novo Nordisk to discover novel peptide therapeutics, a ligand identified by Kallyope has been licensed by Novo Nordisk for further development, including as a potential new mechanism for the treatment of obesity. This is a significant scientific milestone stemming from the
Kallyope Frequently Asked Questions (FAQ)
When was Kallyope founded?
Kallyope was founded in 2015.
Where is Kallyope's headquarters?
Kallyope's headquarters is located at 430 East 29th Street, New York.
What is Kallyope's latest funding round?
Kallyope's latest funding round is Grant.
How much did Kallyope raise?
Kallyope raised a total of $487.2M.
Who are the investors of Kallyope?
Investors of Kallyope include Bill & Melinda Gates Foundation, Polaris Partners, Alexandria Venture Investments, The Column Group, Lux Capital and 15 more.
Loading...
Loading...